Annual Conference 2013

230 - Understanding Emerging Treatment Options for Advanced Prostate Cancer: Goals and Considerations for Nurses

Oct 13, 2013 12:15pm ‐ Oct 13, 2013 1:45pm

Standard: $20.00
Members: $0.00

Description

This program will provide information about the application, efficacy, and safety of these new and emerging CRPC treatment options in order to provide sufficient care, support, and information to patients.This program will provide information about the application, efficacy, and safety of these new and emerging CRPC treatment options in order to provide sufficient care, support, and information to patients.

Purpose: This program will provide information about the application, efficacy, and safety of these new and emerging CRPC treatment options in order to provide sufficient care, support, and information to patients.

This education activity is co-provided by SUNA and PleXus Communications.

Society of Urologic Nurses and Associates is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

SUNA is a provider approved by the California Board of Registered Nursing, Provider Number CEP5556.

1.5 CH is awarded for this CNE activity (includes 1 CH of Pharmacology Content)  

Contact hours available until 10/11/2015.

Requirements for Successful Completion:
Complete the learning activity in its entirety and complete the online CNE evaluation.

Faculty, Planners, and Authors Conflict of Interest Disclosure:
Lee Ann Boyd, MSN, ARNP-C, CUNP
Presenter Bureau: Warner Chilcott

Leanne Schimke, MSN, CRNP-C, CUNP
Presenter: Amgen-Xgeva, Warner Chilcott-Enablex

Leonard Gomella, MD, FACS, has disclosed having financial arrangements or affiliations with the following commercial
interest(s) whose products or services may be mentioned in this activity.
Grant/Research Support: Janssen, Amgen
Consultant/Presenter Bureau: Janssen, Dendreon, Astellas, Bayer
Scientific Advisory: Sanofi Aventis

There are no other disclosures to declare.

Commercial Support and Sponsorship:
Supported by unrestricted educational grants from Bayer HealthCare, Janssen
Biotech, Inc., and Astellas Pharma US, Inc. & Medivation, Inc.

Objectives:

  • Summarize the new and novel agents used for the treatment of prostate cancer that has progressed during androgen-blockade.
  • Recognize, understand, and treat complications associated with CRCP treatment regimens.
  • Identify bone compromise in patients with prostate cancer, provide information on how to minimize bone loss, and encourage patients to adopt lifestyle changes that will improve their quality of life and decrease their fracture risk.
  • Educate and counsel patients regarding bone health in prostate cancer and compare and contrast available treatment options.

Speaker(s):

Speaker(s):

You must be logged in and own this session in order to post comments.